Finally, inhibition of BCR signaling via treatment with ibrutinib or via inhibition of SYK significantly inhibits both CD40- and CpG-mediated CLL proliferation in vitro, showing the role of BCR-associated kinases (36, 107, 131). This evidence concerns the gene SYK and B-cell chronic lymphocytic leukemia.